MONTREAL, QC / ACCESSWIRE / June 18, 2018 / Sunshine Biopharma, Inc. (OTC PINK: SBFM), a pharmaceutical company
focused on the research, development and commercialization of drugs for the treatment of cancer, today announced that it has
purchased all of the necessary equipment for Microbiology Testing Service and will be launching the service through its wholly
owned subsidiary, Atlas Pharma Inc. Presently, Atlas Pharma offers analytical chemistry testing.
"This is in line with our stated plans to expand the operations of Atlas. Microbiology Testing is one of the most frequently
requested analytical tests for most industrial samples," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "We are pleased to
be adding this new milestone in the growth of our firm," he added.
About Atlas Pharma
Atlas Pharma Inc. was founded in 2012 and acquired by Sunshine Biopharma in January 2018. The company offers analytical
chemistry testing services to the pharmaceutical, cosmetic and natural products industry. Atlas has 9 full-time employees and
operates in a 5,250 square foot facility located in Montreal (Canada). Atlas Pharma operations are authorized by a Drug
Establishment License (DEL) issued by Health Canada and are fully compliant with the requirements of Good Manufacturing Practices
(GMP). Atlas Pharma is also registered with the FDA. More information about Atlas Pharma is available at www.atlaspharmainc.ca.
About Sunshine Biopharma
Sunshine Biopharma is pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the
research, development and commercialization of drugs for the treatment of cancer. Sunshine Biopharma's business plan includes the
clinical development of Adva-27a, the Company's proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the
drug's effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer
cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted
at McGill University's Jewish General Hospital in Montreal, Canada.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or
otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain
risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
